Cardiovascular effects of psychotic illnesses and antipsychotic therapy

Area of Science:

• Cardiology
• Psychiatry
• Pharmacology

Background:

• Increased cardiovascular disease (CVD) mortality is observed in individuals with mental health disorders, particularly schizophrenia.
• Antipsychotic medications and schizophrenia itself contribute to cardiac risks beyond traditional factors.
• Cardiac autonomic dysfunction and metabolic syndrome are prevalent in schizophrenia, reducing life expectancy.

Purpose of the Study:

• To review the multifactorial causes of increased cardiovascular mortality in schizophrenia patients.
• To discuss the cardiac side effects of antipsychotic medications, including pro-arrhythmic and metabolic impacts.
• To highlight the need for multifaceted cardiovascular risk management in this population.

Main Methods:

• Literature review on cardiovascular risks associated with schizophrenia and its treatments.
• Analysis of cardiac side effects of traditional and newer antipsychotics.
• Discussion of specific concerns like clozapine-induced cardiomyopathy and hERG channel effects.

Main Results:

• Antipsychotics can cause cardiac side effects, including pro-arrhythmia (hERG channel) and metabolic syndrome.
• Schizophrenia is linked to cardiac autonomic dysfunction, increasing CVD risk.
• Clozapine carries a risk of dose-independent cardiomyopathy requiring monitoring.

Conclusions:

• Managing cardiovascular risk in schizophrenia necessitates a multifaceted and nuanced strategy.
• Balancing effective mental illness treatment with acceptable cardiovascular risk is crucial.
• Practical measures for clinical cardiologists are presented to aid patient management.